Search
1 article for “Imatinib resistant Chronic myelogenous leukaemia (CML)”
-
Dasatinib Induced Pulmonary Hypertension
Abstract: Dasatinib (Das) is a second-generation tyrosine kinase inhibitor that is used in the treatment of chronic myelogenous leukemia (CML) in patients who are resistant or intolerant to imatinib, as well as in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. Dasatinib-induced pulmonary arterial hypertension (PAH) is a known but rare adverse effect of dasatinib and is grouped under Group-1 PAH. The mechanism of PAH development is not fully known, but …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 14, Issue 3, 2024 · pp. 92–95 Read article